WO2013066181A1 - Ligands d'imagerie - Google Patents
Ligands d'imagerie Download PDFInfo
- Publication number
- WO2013066181A1 WO2013066181A1 PCT/NL2012/050768 NL2012050768W WO2013066181A1 WO 2013066181 A1 WO2013066181 A1 WO 2013066181A1 NL 2012050768 W NL2012050768 W NL 2012050768W WO 2013066181 A1 WO2013066181 A1 WO 2013066181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- compound according
- pyridinyl
- hydrogen
- Prior art date
Links
- 238000003384 imaging method Methods 0.000 title claims abstract description 23
- 239000003446 ligand Substances 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 89
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims abstract description 14
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims abstract description 14
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 14
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000001514 detection method Methods 0.000 claims abstract description 13
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 125000001424 substituent group Chemical group 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims description 19
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 13
- -1 2-pyridinyl Chemical group 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 238000012634 optical imaging Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000002600 positron emission tomography Methods 0.000 claims description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 208000037259 Amyloid Plaque Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 230000008499 blood brain barrier function Effects 0.000 description 9
- 210000001218 blood-brain barrier Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-YYWVXINBSA-N N,N-dimethylformamide-d7 Chemical compound [2H]C(=O)N(C([2H])([2H])[2H])C([2H])([2H])[2H] ZMXDDKWLCZADIW-YYWVXINBSA-N 0.000 description 4
- XFFSCOOTVXBLCK-QAVVBOBSSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O XFFSCOOTVXBLCK-QAVVBOBSSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 3
- QNBHEIJDVCXPFV-UHFFFAOYSA-N C1=CC=CC2=CC=C(C=3C(=C(CCC=3)N)C=C3)C3=C21 Chemical compound C1=CC=CC2=CC=C(C=3C(=C(CCC=3)N)C=C3)C3=C21 QNBHEIJDVCXPFV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- NGQSLSMAEVWNPU-UHFFFAOYSA-N 1,2-bis(2-phenylethenyl)benzene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1C=CC1=CC=CC=C1 NGQSLSMAEVWNPU-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- FGYNZFHVGOFCMD-KHVHPYDTSA-N 4-[(e)-2-[4-[(e)-2-(4-hydroxyphenyl)ethenyl]-3-methoxyphenyl]ethenyl]phenol Chemical compound C=1C=C(\C=C\C=2C=CC(O)=CC=2)C(OC)=CC=1\C=C\C1=CC=C(O)C=C1 FGYNZFHVGOFCMD-KHVHPYDTSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012216 imaging agent Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RBZMSGOBSOCYHR-UHFFFAOYSA-N 1,4-bis(bromomethyl)benzene Chemical compound BrCC1=CC=C(CBr)C=C1 RBZMSGOBSOCYHR-UHFFFAOYSA-N 0.000 description 1
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000018282 ACys amyloidosis Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000002616 MRI contrast agent Substances 0.000 description 1
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical class [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XUXNAKZDHHEHPC-UHFFFAOYSA-M sodium bromate Chemical compound [Na+].[O-]Br(=O)=O XUXNAKZDHHEHPC-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Definitions
- the invention is directed to a compound for use as an imaging ligand for the detection of aggregated amyloid- ⁇ or for use as a medicament.
- Imaging ligands are used in various imaging methods, such as optical imaging,for example multiphoton microscopy, 19F MRI methods, PET and SPECT imaging.
- Suitable compounds have a good solubility in aqueous systems and have a good blood-brain barrier (BBB) passage next to a good selectivity for amyloid deposits.
- BBB blood-brain barrier
- the compounds will require special properties, such as fluorescence or a radioactive label, to be able to detect them with the specific imaging method for which they are designed.
- An example of a compound known for use as an imaging ligand for the detection of aggregated amyloid is the optical imaging agent Methoxy X-04 compound as described in Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST,
- US-B-7029655 describes (trans, trans)-1 -bromo-2,5-bis-(3- hydroxycarbonyl-4-hydroxy)-stryrylbenzene as a ligand for use in MRI methods for detecting amyloid deposits associated with Alzheimer's disease.
- WO-A-2007/034757 describes a styrylbenzene derivate which has an effect of inhibiting the coagulation or fibrosis of an amyloid protein. The compound may be used to treat an amyloid related disease.
- WO-A-2005/042461 describes a styrylbenzene compound which is capable of fluorescent staining of amyloid and which can be used as an amyloid- specific MRI contrast agent.
- the object of the present invention is to find a compound having similar or even improved affinity to amyloid plaques .
- R1 and may be the same or different optionally substituted pyridinyl group and wherein R ⁇ is hydrogen or a substituent group comprising at least an oxygen atom and/or a fluor atom.
- the above compounds can be used as imaging ligands for the detection of aggregated amyloid- ⁇ . Because of their affinity to the aggregated amyloid- ⁇ the compound may also find use as medicament. Further advantages and preferred embodiments will be described below. Apart from ⁇ F for MRI detectability, all developed compounds have fluorescent properties, which make them suitable for optical imaging methods, such as multiphoton microscopy. Further advantages of the invention will be described below.
- the invention further provides a sensitive and non-invasive method to diagnose Alzheimer's disease at an early stage.
- MRI methods are based on water signals, but as water is abundant in living systems, background signals can be a problem. ⁇ F is virtually not present in biological systems, and therefore a low background signal is expected, which makes image analysis easier and unambiguous.
- R1 and R1 may be combinations of an optionally substituted pyridinyl group, wherein the pyridinyl group may be described as below.
- R1 and R ⁇ are same or different optionally substituted pyridinyl groups. More preferably R1 and
- R3 are the same optionally substituted pyridinyl group.
- the pyridinyl groups make the compounds less lipophilic, which translates into better solubility in aqueous systems and an improved blood-brain barrier (BBB) passage.
- BBB blood-brain barrier
- Examples of preferred pyridinyl groups are 2- pyridinyl, 3-pyridinyl and 4- pyridinyl. Good results have been observed when both R1 and R ⁇ are 3-pyridinyl.
- R ⁇ is preferably either hydrogen, a hydroxyl group, alkoxy group having 1 to 5 carbon atoms, preferably 1-2 carbon atoms and more preferably methoxy, or a fluoroalkyi group having 1 to 5 carbon atoms and one to three fluor atoms, preferably 1 -2 carbon atoms and more preferably tri-fluoromethyl or a fluorinated alkoxy group having 1 to 5 carbon atoms of which at least one carbon atom is substituted with 3 fluor atoms. Examples of compounds according to the first embodiment are shown in Figure 2.
- the invention is also directed to compositions comprising the above compound and especially directed to pharmaceutical compositions comprising the above compound, salt or solvate thereof and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent.
- the compound may be
- the compound after purification, may be diluted with water or water containing such as, but not limited to, sodium hydroxide or hydrogen chloride.
- the diluted fraction as prepared is trapped on a Seppak® like, but not limited to, C18, tC18, Silica or an Oasis Seppak® and the compound is preferably eluted from the Seppak® with a solvent suitable for injection in vivo, like ethanol.
- the obtained eluate is preferable diluted with pharmaceutically acceptable buffers such as, but not limited to 0.9% sodium chloride, sodiumdihydrogenphosphate 7.09 mM in 0.9 % sodiumchloride or citrate buffer, pharmaceutically acceptable solubilisers such as, but not limited to, ethanol, tween or phospholipids and/or with pharmaceutically acceptable stabilizers or antioxidants such as, but not limited to, ascorbic acid, gentisic acid or p-aminobenzoic acid.
- pharmaceutically acceptable buffers such as, but not limited to 0.9% sodium chloride, sodiumdihydrogenphosphate 7.09 mM in 0.9 % sodiumchloride or citrate buffer
- pharmaceutically acceptable solubilisers such as, but not limited to, ethanol, tween or phospholipids
- pharmaceutically acceptable stabilizers or antioxidants such as, but not limited to, ascorbic acid, gentisic acid or p-aminobenzoic acid.
- the invention is directed to a compound for use as an imaging ligand for the detection of aggregated amyloid- ⁇ in an in vivo diagnosis.
- the invention is directed to the use of the above compound or a formulation comprising the compound as an imaging ligand for the detection of aggregated amyloid- ⁇ , preferably in an in vivo diagnosis. More preferably to the use in a method for in vivo diagnosis of an amyloid related disease in a subject, preferably a human, comprising administration of the above compound or formulation, suitably a pharmaceutical formulation comprising the compound and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluents, and performing an imaging method. All compounds or formulations have fluorescent properties, making them suitable for optical imaging techniques, such as but not limited to multiphoton microscopy, in vivo fluorescence imaging and fluorescence microscopy. The invention is thus also directed to a method wherein the imaging method is an optical imaging method.
- the compound comprises one or more substituent groups comprising one or more fluor atoms.
- a further preferred imaging method is positron emission tomography (PET) or single photon emission computed tomography (SPECT). These methods use radiolabeled compounds.
- PET positron emission tomography
- SPECT single photon emission computed tomography
- the compound has one or more substituent groups such as, but not limited to, one or more of
- the compound has a group
- R2 comprising one or one I ⁇ F atom.
- radiolabeled compounds can be advantageously used as diagnostic imaging agents for in vivo imaging of aggregated amyloid- ⁇ using said PET and SPECT methods.
- the compounds described above or pharmaceutical compositions comprising said compound may also be used as a medicament. More preferably the compounds described above or compositions comprising said compound are used in treating or prevention of Alzheimer's disease, mild cognitive impairment, Down's syndrome, mild cognitive impairment in Down's syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, other degenerative dementias, dementias of mixed vascular and degenerative origin, dementia associated with Parkinson's disease, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration, diffuse Lewy body type of Alzheimer's disease.
- the use is prevention or treatment of Alzheimer's disease.
- R1 and R ⁇ may be the same or different optionally substituted
- R ⁇ is hydrogen or a substituent group comprising at least an oxygen atom or a fluor atom.
- R.1 and R ⁇ are different or more preferably the same optionally substituted 3-pyridinyl group.
- the pyridinyl groups make the compounds less lipophilic, which translates into better solubility in aqueous systems and an improved blood-brain barrier (BBB) passage.
- BBB blood-brain barrier
- R ⁇ is preferably either hydrogen, a hydroxyl group, alkoxy group having 1 to 5 carbon atoms, preferably 1 -2 carbon atoms and more preferably methoxy, or a fluoroalkyl group having 1 to 5 carbon atoms and one to three fluor atoms, preferably 1 -2 carbon atoms and more preferably tri-fluoromethyl or a fluorinated alkoxy group having 1 to 5 carbon atoms of which at least one carbon atom is substituted with 3 fluor atoms.
- R ⁇ is preferably a hydrogen, a methoxy or a tr-fluoromethyl group.
- the invention shall be illustrated with the below non-limiting examples.
- the examples will include the synthesis of a set of compounds in Example 1 , a comparison of the properties of said compounds in Example 2 and Examples 3 and 4 illustrating the use of said compound as ligand for the detection of
- Reactions were monitored by thin layer chromatography on aluminum coated silica sheets (Merck, silica 60 F254), using visualization either with iodine, or spraying with a solution of 25 g ( ⁇ 10 g (NH4)4Ce(S04)4 in 100 ml H2SO4 and 900 ml H2O, or a solution of 20% H2SO4 in ethanol, followed by charring at -150 °C.
- the high resolution mass spectrometer was calibrated prior to
- LC-MS analysis was performed on a Finnigan Surveyor HPLC system with a Gemini C18 50 ⁇ 4.6 mm column (3 micron, Phenomenex, Torrance, CA, USA) (detection at 200-600 nm), coupled to a Thermo Finnigan LCQ Advantage Max mass spectrometer (Breda, The Netherlands) with electrospray ionization (ESI; system 1 ) was used, with the same buffers as described above.
- ESI electrospray ionization
- the compounds according to the first embodiment are preferably prepared by a scheme as illustrated in Figure 1 . Reference will be made to this scheme in describing this Example. This example describes the synthesis wherein R1 and R 3 are 4-pyridinyl groups and R ⁇ is hydrogen.
- Tetraethyl 1 ,4-xylylene diphosphonate (34 in Figure 1 ) was obtained as white fluffy powder (5.6 g, 14.8 mmol, 74% over two steps) and had the following properties: H NMR (CDCI3, 400 MHz) ⁇ 7.25 (s, 4H); 4.07-3.95 (m,
- LogP values were determined for some of the compounds.
- the LogP value is an indicator for Blood Brain Barrier (BBB) passage.
- LogP determinations were performed using literature procedures (Benhaim, D.; Grushka, E. J. Chrom. A 2008, 1209, 1 1 1 -1 19).
- Table 2 shows some results for the LogP values and % intensity relative to the prior art MethX04 dye which are relevant for a dye for the detection of aggregated amyloid- ⁇ .
- Affinity for amyloid plaque was assessed qualitatively by staining human and mouse brain sections with the developed compounds.
- Solutions of the compounds (1 , 10 and 100 ⁇ ) were applied to brain slices of APP/PS1 mice bearing ⁇ plaques and human AD sections.
- Fluorescence microscopy was used to score the specificity for amyloid plaque based on the compounds' fluorescence, and to assess non-specific background staining.
- FIG. 3 A compound according to Figure 3a was used to stain amyloid plaque in APP/PS1 mouse brain. Direct staining of tissue sections showed high affinity and specificity of this compound for amyloid plaque with fluorescence microscopy. See results in Figure 3B.
- Ki values were assessed by a competition assay on fibrilized synthestic ⁇ 1 -40, as well as on APP/PS1 mouse brain homogenates to test the properties of the compound according to Figure 3A.
- the competing amyloid- targeting ligand was 3H-Chrysamine G, a known amyloid-binding ligand.
- the mixture was sonicated for 10 min, and the assay was subsequently initiated by the addition of 50 ⁇ synthetic ⁇ 1 -40 fibrils, to achieve final concentrations of 5 nM [3H]Chrysamine-G and 50 nM fibrils.
- Identical experiments were performed using mouse brain cortex homogenate instead of synthetic ⁇ 1 -40 fibrils.
- Nonspecific binding was determined in the presence of 1 ⁇ M-X04. Incubations were terminated after 1 h via filtration through Whatman GF/B filters (pre-soaked in binding buffer), using a 48-well Brandel harvester.
- the filters were washed two times with 3 ml of ice-cold binding buffer (pH 7.0), and radioactivity was determined by liquid scintillation spectrometry in 5 ml of Optiphase-HiSafe 3, at an efficiency of 40 %.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne un composé ou son sel ou son solvate, à utiliser en tant que ligand d'imagerie pour la détection d'amyloïde-β agrégé ou en tant que médicament selon la formule (I): Dans ladite formule, R1 et R3 peuvent représenter le même groupe pyridinyle éventuellement substitué ou un groupe pyridinyle éventuellement substitué différent, et R2 représente un hydrogène ou un groupe substituant comprenant au moins un atome d'oxygène ou un atome de fluor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2007714 | 2011-11-04 | ||
NL2007714A NL2007714C2 (en) | 2011-11-04 | 2011-11-04 | Imaging ligands. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013066181A1 true WO2013066181A1 (fr) | 2013-05-10 |
Family
ID=47215703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL2012/050768 WO2013066181A1 (fr) | 2011-11-04 | 2012-11-02 | Ligands d'imagerie |
Country Status (2)
Country | Link |
---|---|
NL (1) | NL2007714C2 (fr) |
WO (1) | WO2013066181A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109776583A (zh) * | 2019-01-25 | 2019-05-21 | 郑州大学 | 一种吡啶类链状共轭体系分子衍生物及其制备方法和应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042461A1 (fr) | 2003-10-30 | 2005-05-12 | Dojindo Laboratories | Compose presentant une affinite avec l'amyloide |
US7029655B2 (en) | 2000-10-04 | 2006-04-18 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
WO2007034757A1 (fr) | 2005-09-20 | 2007-03-29 | Fuence Co., Ltd. | Remède pour des maladies amyloïdes et médicament pour le suivi de celles-ci |
WO2008144065A1 (fr) * | 2007-05-21 | 2008-11-27 | Neuroptix Corporation | Formulations ophtalmiques d'agents de contraste amyloïde et procédés d'utilisation de celles-ci |
WO2010141704A2 (fr) * | 2009-06-04 | 2010-12-09 | General Electric Company | Imagerie de la protéine basique de la myéline |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19506043A1 (de) * | 1995-02-22 | 1996-08-29 | Bayer Ag | Polymere mit Distyrylbenzoleinheiten und deren Verwendung |
-
2011
- 2011-11-04 NL NL2007714A patent/NL2007714C2/en not_active IP Right Cessation
-
2012
- 2012-11-02 WO PCT/NL2012/050768 patent/WO2013066181A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029655B2 (en) | 2000-10-04 | 2006-04-18 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
WO2005042461A1 (fr) | 2003-10-30 | 2005-05-12 | Dojindo Laboratories | Compose presentant une affinite avec l'amyloide |
WO2007034757A1 (fr) | 2005-09-20 | 2007-03-29 | Fuence Co., Ltd. | Remède pour des maladies amyloïdes et médicament pour le suivi de celles-ci |
WO2008144065A1 (fr) * | 2007-05-21 | 2008-11-27 | Neuroptix Corporation | Formulations ophtalmiques d'agents de contraste amyloïde et procédés d'utilisation de celles-ci |
WO2010141704A2 (fr) * | 2009-06-04 | 2010-12-09 | General Electric Company | Imagerie de la protéine basique de la myéline |
Non-Patent Citations (12)
Title |
---|
BENHAIM, D.; GRUSHKA, E., J. CHROM. A, vol. 1209, 2008, pages 111 - 119 |
COHEN A D ET AL: "Anti-amyloid effects of small molecule A[beta] -binding agents in PS1/APP", LETTERS IN DRUG DESIGN AND DISCOVERY, BENTHAM SCIENCE PUBLISHERS, US, vol. 6, no. 6, 1 September 2009 (2009-09-01), pages 437 - 444, XP009157383, ISSN: 1570-1808, DOI: 10.2174/157018009789057526 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1972, HASEGAWA, MASAKI ET AL: "1,4-Bis(aryl-2-vinyl)benzene derivatives", XP002689388, retrieved from STN Database accession no. 1972:463349 * |
FLAHERTY DANIEL P ET AL: "Phenolic bis-styrylbenzenes as [beta]-amyloid binding ligands and free radical scavengers.", JOURNAL OF MEDICINAL CHEMISTRY 25 NOV 2010 LNKD- PUBMED:21038854, vol. 53, no. 22, 25 November 2010 (2010-11-25), pages 7992 - 7999, XP002671936, ISSN: 1520-4804 * |
FLAHERTY DANIEL P ET AL: "Polyfluorinated bis-styrylbenzene beta-amyloid plaque binding ligands", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 50, no. 20, 4 October 2007 (2007-10-04), pages 4986 - 4992, XP002491891, ISSN: 0022-2623, [retrieved on 20070911], DOI: 10.1021/JM070085F * |
FLAHERTY DP; WALSH SM; KIYOTA T; DONG Y; IKEZU T: "Vennerstrom JL. Polyfluorinated bis-styrylbenzene beta-amyloid plaque binding ligands.", J MED CHEM., vol. 50, no. 20, 4 October 2007 (2007-10-04), pages 4986 - 92 |
KHAN ET AL: "O-H...N Heterosynthon: a robust supramolecular unit for crystal engineering", CRYSTAL GROWTH AND DESIGN, vol. 9, no. 5, 23 March 2009 (2009-03-23), pages 2354 - 2362, XP002671938 * |
KLUNK W E ET AL: "IMAGE ABETA PLAQUES IN LIVING TRANSGENIC MICE WITH MULTIPHOTON MICROSCOPY AND METHOXY-X04, A SYSTEMICALLY ADMINISTERED CONGO RED DERIVATIVE", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, LIPPINCOTT WILLIAMS AND WILKINS, NEW YORK, NY, vol. 61, no. 9, 1 September 2002 (2002-09-01), pages 797 - 805, XP008031463, ISSN: 0022-3069 * |
KLUNK WE; BACSKAI BJ; MATHIS CA; KAJDASZ ST; MCLELLAN ME; FROSCH MP; DEBNATH ML; HOLT DP; WANG Y; HYMAN BT: "Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative", J NEUROPATHOL EXP NEUROL., vol. 61, no. 9, September 2002 (2002-09-01), pages 797 - 805, XP008031463 |
MARRI E ET AL: "Triplet-sensitized photobehaviour of the three stereoisomers of 1,4-distyrylbenzene and some aza-analogues", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY, A: CHEMISTRY, ELSEVIER SEQUOIA, LAUSANNE, CH, vol. 177, no. 2-3, 25 January 2006 (2006-01-25), pages 307 - 313, XP028008562, ISSN: 1010-6030, [retrieved on 20060125], DOI: 10.1016/J.JPHOTOCHEM.2005.06.010 * |
PIYUSH KUMAR ET AL: "18F-FESB: synthesis and automated radiofluorination of a novel18F-labeled pet tracer for[beta]-amyloid plaques", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 48, no. 13, 1 November 2005 (2005-11-01), pages 983 - 996, XP055006268, ISSN: 0362-4803, DOI: 10.1002/jlcr.1011 * |
SATO K ET AL: "Fluoro-substituted and <13>C-labeled styrylbenzene derivatives for detecting brain amyloid plaques", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 39, no. 7, 1 July 2004 (2004-07-01), pages 573 - 578, XP004518629, ISSN: 0223-5234, DOI: 10.1016/J.EJMECH.2004.02.013 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109776583A (zh) * | 2019-01-25 | 2019-05-21 | 郑州大学 | 一种吡啶类链状共轭体系分子衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
NL2007714C2 (en) | 2013-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102464274B1 (ko) | 진단 및 치료를 위한 바이사이클릭 화합물 | |
EP2501696B1 (fr) | Agents pour l'imagerie et leur utilisation pour le diagnostic in vivo de maladies neurodégénératrices, notamment la maladie d'alzheimer et des maladies apparentées | |
ES2427963T3 (es) | Uso de derivados de tioflavina radiomarcados en formación de imágenes de amiloide para evaluación de las terapias antiamiloide | |
Sato et al. | Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques | |
JP6194416B2 (ja) | タウ−petリガンドとしてのジアザカルバゾール誘導体 | |
KR20010031872A (ko) | 알츠하이머 병을 죽기 전에 진단하고, 아밀로이드 침적을생체내에서 단층촬영하고 예방하기 위한 화합물 | |
CA2715390A1 (fr) | Agents d'imagerie pour la detection d'une dysfonction neurologique | |
CN109475648B (zh) | 用于成像tau蛋白聚集体的化合物 | |
JP2004506723A (ja) | アルツハイマー病の生前診断ならびにアミロイド沈着物のインビボ画像化および予防に用いるためのチオフラビン誘導体 | |
US20110071301A1 (en) | Abeta-binding small molecules | |
WO2010098502A1 (fr) | Agent de diagnostic par imagerie et agent de diagnostic extracorporel pour des maladies neurologiques incurables | |
WO2007148755A1 (fr) | Nouveau composé presentant une affinité pour une substance amyloïde | |
Nabuurs et al. | Polyfluorinated bis-styrylbenzenes as amyloid-β plaque binding ligands | |
CA2764366C (fr) | Imagerie de la proteine basique de la myeline | |
JP2021512070A (ja) | Pet画像化のための診断用組成物、診断用組成物を製造するための方法及び診断におけるその使用 | |
MXPA06001742A (es) | Sondas para enfermedades en las cuales se acumula amiloide, agentes para tincion del amiloide, farmacos para tratamiento y profilaxis de enfermedades con amiloide acumulado, y sondas para diagnostico de ovillos neurofibrilares y agentes para tincion | |
JP2024529358A (ja) | Tdp-43タンパク質症の診断のための新規化合物 | |
JP2012507534A (ja) | 新規置換アザベンゾオキサゾール類 | |
WO2013066181A1 (fr) | Ligands d'imagerie | |
US20090004107A1 (en) | Beta-amyloid and neurofibrillary tangle imaging agents | |
WO2023104148A1 (fr) | SONDE À PETITES MOLÉCULES SE LIANT À L'AGRÉGAT D'α-SYNUCLÉINE ET APPLICATION DE CELLE-CI | |
EP2216052A1 (fr) | Utilisation d'un nouveau composé présentant une affinité pour les substances amyloïdes et procédé de production dudit composé | |
JP2021512064A (ja) | 画像化化合物を調製する新規方法 | |
JP7059270B2 (ja) | タウタンパク質凝集体を画像化するための化合物 | |
Nabuurs et al. | Bis-pyridylethenyl benzene as novel backbone for amyloid-β binding compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12788308 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12788308 Country of ref document: EP Kind code of ref document: A1 |